Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Beta-mannosidosis is a very rare lysosomal storage disease characterized by developmental delay of varying severity and hearing loss, but that can manifest a wide phenotypic heterogeneity.
Data assembled from 8 of 12 sources · Last updated Oct 3, 2026, 8:09 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Features include always present findings: Decreased circulating beta-mannosidase activity, Hyperactivity, and Reduced tissue beta-mannosidase activity; and very common findings: Hearing loss (hearing impairment), Seizure, Abnormal facial shape, and Intellectual disability and others. 18 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Abnormal speech pattern, Seizure, Aggressive behavior |
Muscles | 2 | Low muscle tone (hypotonia), Generalized hypotonia |
Blood and immune system | 2 | Recurrent infections, Recurrent respiratory infections |
Skin | 1 | Angiokeratoma |
Ears | 1 | Hearing loss (hearing impairment) |
Lab test results | 1 | Decreased circulating beta-mannosidase activity |
Kidneys and urinary system | 1 | Increased urinary disaccharide excretion |
Head and neck | 1 | Abnormal facial shape |
Eyes | 1 | Tortuosity of conjunctival vessels |
Lungs and breathing | 1 | Recurrent respiratory infections |
Digestive system | 1 | Hypoplasia of the abdominal wall musculature |
MANBA encodes mannosidase beta (879 aa). Exoglycosidase that cleaves the single beta-linked mannose residue from the non-reducing end of all N-linked glycoprotein oligosaccharides Highest expression in Spleen (35.2 TPM) and Lung (34.6 TPM).
Beta-mannosidosis is caused by mutations in the MANBA gene on chromosome 4.
The MANBA protein participates in MANBA hydrolyses GlcNAc:Man pathway.
MANBA is classified as a druggable target (Druggable Genome and Enzyme categories) with score 0.0.
Genetic testing for MANBA is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 always present features, 6 very common features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
6 publications have been identified in PubMed for beta-mannosidosis. Research spans Other (20%), Review / Meta-Analysis (20%), and Basic Science / Preclinical (20%).
Xi J (2026). [PMID: 41678453](https://pubmed.ncbi.nlm.nih.gov/41678453/). *PloS one*. [Gene Therapy / Novel Therapeutics]
Bezerra FCM (2026). [PMID: 42017430](https://pubmed.ncbi.nlm.nih.gov/42017430/). *Anim Genet*. [Basic Science / Preclinical]
Casazza K (2026). [PMID: 42008923](https://pubmed.ncbi.nlm.nih.gov/42008923/). *Mol Genet Metab*. [Review / Meta-Analysis]
Farrell EE (2025). [PMID: 40464095](https://pubmed.ncbi.nlm.nih.gov/40464095/). *Vet Clin Pathol*. [Other]
Martin Rios AM (2025). [PMID: 41235131](https://pubmed.ncbi.nlm.nih.gov/41235131/). *Neurology. Genetics*. [Epidemiology / Natural History]